Creutzfeldt-Jakob disease and advanced therapy medicinal products - Scientific guideline
Table of contents
This document considers the risk of transmitting Creutzfeldt-Jakob disease (CJD) or variant CJD agents via the advanced therapy medicinal products.
Keywords: Creutzfeldt-Jakob disease, gene therapy, cell therapy and tissue engineering medicinal products, donor selection criteria, tissue and blood donation
-
List item
CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced-therapy medicinal products (PDF/68.92 KB)
Adopted
First published: 28/06/2011
Last updated: 28/06/2011
EMA/CHMP/BWP/353632/2010 -
List item
Overview of comments received on 'CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced-therapy medicinal products' (PDF/76.41 KB)
First published: 28/06/2011
Last updated: 28/06/2011
EMA/CHMP/BWP/782739/2010 -
List item
Draft CHMP/CAT position statement on Creutzfeldt-Jakob disease and advanced therapy medicinal products (PDF/72.37 KB)
Draft: consultation closed
First published: 27/07/2010
Last updated: 27/07/2010
Consultation dates: 24/06/2010 to 30/09/2010
EMA/CHMP/CAT/BWP/353632/2010